マイページへログイン
薬学研究分野の英文校正サンプル
エナゴは、薬学研究分野でも多くの論文を校正し、高い評価をいただいてきました。主に医薬品の製造、調剤、評価などを行う薬学研究から、計数調剤、生物統計学、製薬バイオテクノロジーなどの関連分野に関する専門知識を有する校正者が、校閲・校正を行います。こちらが薬学論文の修正履歴付き校正サンプルです。アドバンス英文校正とノーマル英文校正の２つのサービスプランを比較いただき、各種サンプルをPDF形式でダウンロードすることもできます。
All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of informationand content in this document in whole or in part is forbidden unless express permission has been given inwriting by Crimson Interactive Pvt. Ltd.www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de |www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ruPurpose: According to current clinical guidelines, combination therapy of Ffenofibrate and statinscombination therapy is highly recommended by the current clinical guidelines for treatingtreatment ofmixed dyslipidemia. In this study, we formulated an innovative delayed-release preparation offenofibrate was designed to reduce the risk of muscle toxicity, caused by simultaneous administrationof this combination therapy, by altering the pharmacokinetic profile of fenofibrate, as well asand toimprove the oral bioavailability of the modified-release formulation.Methods: Micronized fFenofibrate was used micronized and used to prepare drug-loaded cores via apowder powder-layering process before performing multiparticulate pellet coating. Different coatingformulations were screened, and their in vitro release profiles was were compared with those of thecommercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated inBeagle dog models using and compared with two reference commercial preparations of fenofibrate,Lipanthyl® (the immediate-release preparation) Lipanthyl® and Lipilfen® (the sustained-releasepellets Lipilfen®) as references.Results: The in vivo release of fenofibrate from R1 and R2 (selected from in vitro tests) exhibited alag phase, which was and thenfollowed by rapid and complete drug release. The relativebioavailabilities of R1 and R2 were (100.4% and 201.1%, respectively), which were higher than thatof Lipilfen® (67.2%).Conclusion: The mModified fenofibrate pellets developed showed enhanced bioavailability anddelayed-release properties. and They have the potential tocan potentially improve safety andcompliance when co-administrated administered with statins. To the best of our knowledge, Tthis isthe first report of a delayed-release preparation of fenofibrate preparation.Comment [A1]: The text alongside has beenrevised to present the intended meaning in aconcise manner by retaining only theinformation that is essential with respect tocontext.Comment [A2]: A compound modifiercontains 2 or more words, which act togetheras one adjective and are connected by hyphens.Hyphens are used with these terms so that theirmeaning is understood clearly.Comment [A3]: In academic writing, it isimportant to maintain parallelism in a sentenceso that the items being compared can be clearlyunderstood. Here, the sentence has beenrevised to clearly denote that “in vitro releaseprofiles” are being compared.Comment [A4]: This phrase was revised tomaintain consistency with the phrase usedpreviously in the text (under “Purpose”).
All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of informationand content in this document in whole or in part is forbidden unless express permission has been given inwriting by Crimson Interactive Pvt. Ltd.www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de |www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ruPurpose: Combination therapy of Ffenofibrate and statins combination therapy is highlyrecommended by the current clinical guidelines for the treatment of mixed dyslipidemia. In this study,we formulated an innovative delayed-release preparation of fenofibrate was designed to achieve thefollowing: to reduce the risk of muscle toxicity, (caused by simultaneous administration of thiscombination therapy), by altering the pharmacokinetic profile of fenofibrate, as well asand to improvethe oral bioavailability of the modified-release formulation.Methods: Micronized fFenofibrate was used micronized to prepare drug-loaded cores via a powderpowder-layering process before performing multiparticulate pellet coating. Different coatingformulations were screened, and their in vitro release profiles was were compared with those of thecommercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated inBeagle dogs using and compared with two reference commercial preparations of fenofibrate (theimmediate-release preparation Lipanthyl® and the sustained-release pellets Lipilfen®) as references.Results: The in vivo release of fenofibrate from R1 and R2 selected from in vitro tests exhibited a lagphase, and thenfollowed by rapid and complete drug release. The relative bioavailabilities of R1 andR2 were 100.4% and 201.1%, respectively, which were higher than that of Lipilfen® (67.2%).Conclusion: The mModified fenofibrate pellets developed showed enhanced bioavailability anddelayed-release properties. and They have the potential tocan potentially improve safety andcompliance when co-administrated administered with statins. To the best of our knowledge, Tthis isthe first report of a delayed-release preparation of fenofibrate preparation.Comment [A1]: A compound modifiercontains 2 or more words, which act togetheras one adjective and are connected by hyphens.Hyphens are used with these terms so that theirmeaning is understood clearly.Comment [A2]: In academic writing, it isimportant to maintain parallelism in a sentenceso that the items being compared can be clearlyunderstood. Here, the sentence has beenrevised to clearly denote that “in vitro releaseprofiles” are being compared.Comment [A3]: This phrase was revised tomaintain consistency with the phrase usedpreviously in the text (under “Purpose”).
月-土 10:00～19:0003-4580-9713
月-日 24時間営業request@enago.com